Advertisement

Topics

Acticor Biotech Confirms Simbec-Orion to Make Its First in Patient Study in Acute Ischemic Stroke

09:53 EDT 14 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, as part of the development of its first drug candidate ACT017 who has just succ...

Other Sources for this Article

Acticor Biotech:
Gilles Avenard
Chief Executive Officer
gilles.avenard@acticor-biotech.com
or
Media – NewCap:
Annie-Florence Loyer
+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59
afloyer@newcap.fr

NEXT ARTICLE

More From BioPortfolio on "Acticor Biotech Confirms Simbec-Orion to Make Its First in Patient Study in Acute Ischemic Stroke"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...